Colchicine in refractory chronic lymphocytic leukemia - A Southwest Oncology Group study

James K. Weick, Robert B. Livingston, Ellis J. Van Slyck

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

Fourteen patients with active chronic lymphocytic leukemia who had failed prior therapy were treated with progressive doses of weekly intravenous colchicine beginning at 2 mg and escalating as high as 7 mg in a single injection. Responses were seen in two of 14, with a lessening of adenopathy and splenomegaly. Toxicity was characterized by gastrointestinal intolerance in eight and thrombocytopenia in 12. There is activity of the drug in chronic lymphocytic leukemia but, as administered in this study, high dose therapy is not ideal and it may be more beneficial if the drug were given as low dose daily or weekly therapy.

Original languageEnglish (US)
Pages (from-to)335-338
Number of pages4
JournalInvestigational New Drugs
Volume1
Issue number4
DOIs
StatePublished - Dec 1 1983

Keywords

  • chronic lymphocytic leukemia
  • colchicine

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Colchicine in refractory chronic lymphocytic leukemia - A Southwest Oncology Group study'. Together they form a unique fingerprint.

  • Cite this